{"product_id":"fatty-liver-disease-isbn-9781405112925","title":"Fatty Liver Disease","description":"\u003cb\u003e\u003ci\u003eFatty Liver Diseases: NASH and Related Disorders\u003c\/i\u003e\u003c\/b\u003e is an unusual book: it combines a practical approach for students and physicians concerned with the problem with a clear overview on the causative mechanisms. It appeals to doctors and other health care workers who encounter this problem, as well as to pathologists and investigators interested in the field of liver disease. \u003cbr\u003e \u003cp\u003e\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eIt will improve your diagnostic acumen for people with abnormal liver tests, advance your knowledge about this important subject and help with your specialist or undergraduate exams, and management of a common disorder.\u003c\/p\u003e  Contributors. \u003cp\u003ePreface.\u003c\/p\u003e \u003cp\u003e1 Overview: an introduction to NASH and related fatty liver disorders.\u003c\/p\u003e \u003cp\u003e2 Pathology of hepatic steatosis, NASH and related conditions.\u003c\/p\u003e \u003cp\u003e3 The epidemiology and risk factors of NASH.\u003c\/p\u003e \u003cp\u003e4 Insulin resistance in NAFLD: potential mechanisms and therapies.\u003c\/p\u003e \u003cp\u003e5 NASH as part of the metabolic (insulin resistance) syndrome.\u003c\/p\u003e \u003cp\u003e6 NASH is a genetically determined disease.\u003c\/p\u003e \u003cp\u003e7 The pathogenesis of NASH: human studies.\u003c\/p\u003e \u003cp\u003e8 Animal models of steatohepatitis.\u003c\/p\u003e \u003cp\u003e9 Fatty acid metabolism and lipotoxicity in the pathogenesis of NAFLD\/NASH.\u003c\/p\u003e \u003cp\u003e10 Cytokines and inflammatory recruitment in NASH: experimental and human studies.\u003c\/p\u003e \u003cp\u003e11 Mitochondrial injury and NASH.\u003c\/p\u003e \u003cp\u003e12 Cell biology of NASH: fibrosis and cell proliferation.\u003c\/p\u003e \u003cp\u003e13 Clinical manifestations and diagnosis of NAFLD.\u003c\/p\u003e \u003cp\u003e14 The clinical outcome of NAFLD including cryptogenic cirrhosis.\u003c\/p\u003e \u003cp\u003e15 Practical approach to the diagnosis and management of people with fatty liver diseases.\u003c\/p\u003e \u003cp\u003e16 Management of NASH: current and future perspectives on treatment.\u003c\/p\u003e \u003cp\u003e17 NAFLD, NASH and orthotopic liver transplantation.\u003c\/p\u003e \u003cp\u003e18 NAFLD\/NASH is not just a ‘Western’ problem: some perspectives on NAFLD\/NASH from the East.\u003c\/p\u003e \u003cp\u003e19 NAFLD\/NASH in children.\u003c\/p\u003e \u003cp\u003e20 Steatohepatitis resulting from intestinal bypass.\u003c\/p\u003e \u003cp\u003e21 Specific disorders associated with NAFLD.\u003c\/p\u003e \u003cp\u003e22 Hepatocellular carcinoma in NAFLD.\u003c\/p\u003e \u003cp\u003e23 Does NASH or NAFLD contribute to comorbidity of other liver diseases?.\u003c\/p\u003e \u003cp\u003e24 Recent advances.\u003c\/p\u003e \u003cp\u003eIndex\u003c\/p\u003e  \"A superb updated review of a topic of dramatically increasing importance, written by leading authorities in the field. The book is well organised and balanced with excellent homogeneity\"\u003cbr\u003e \u003cp\u003e\"A comprehensive book of invaluable help in diagnosing and managing NAFLD\/NASH. Again, an outstanding source of current data concerning this epidemiologically important problem\"\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003ci\u003eDigestive and Liver Disease\u003c\/i\u003e\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\"\u003ci\u003eFatty Liver Disease\u003c\/i\u003e is a state-of-the-art textbook coauthored by a number of top-notch experts and should be viewed as an invaluable contribution to the proper management of fatty liver diseases and all its coexisting conditions.\"\u003c\/p\u003e \u003cp\u003e\u003ci\u003eNew England Journal of Medicine, 353;20 November 2005\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGeoff Farrell, Professor of Hepatic Medicine, Director of Gastroenterology, The Canberra Hospital, Australia\u003c\/b\u003e\u003cbr\u003eGeoffrey Farrell graduated MB BS from the University of Tasmania in 1970, and trained in gastroenterology and hepatology at the Royal Prince Alfred and Royal Brisbane Hospitals, the latter with Lawrie Powell with whom he completed an MD on hepatic drug metabolism. He was awarded an NHMRC CJ Martin Fellowship to conduct post-doctoral research in UCSF, and in 1980 returned to Sydney to establish a Liver Research Group at Westmead Hospital. He was promoted to a personal chair in 1993, then accepted the Storr Chair in Hepatic Medicine. He remained Director of the Storr Liver Unit until Jan 2006, when he accepted the position as Professor of Hepatic Medicine with ANU Medical School and Director of Gastroenterology and Hepatology at The Canberra Hospital. He has held many leadership roles in medical research, gastroenterology, editorial boards, and academic medicine, including Editor-in-Chief of \u003ci\u003eJournal of Gastroenterology and Hepatology\u003c\/i\u003e since November 2006.\u003cbr\u003eGeoff Farrell's research interests are in non-alcoholic steatohepatitis, viral hepatitis, drug-induced liver injury, and liver regeneration. He has published 3 books, including the first on non-alcoholic fatty liver disease, and written more than 180 scientific papers and 100 reviews\/chapters and editorials in the fields of hepatology and biochemical pharmacology. His work is very highly cited, with an H-index of 50, more than 20 articles cited \u0026gt;100 times, average citation 32 per paper, and 15 articles being the subject of editorials in major medical journals. He is CIA on an NHMRC Program Grant to study the molecular and cellular basis of liver disease, and has recently held a Centre for Clinical Research Excellence Program grant to improve outcomes for patients with liver disease.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eJacob George\u003c\/b\u003e is the editor of \u003ci\u003eFatty Liver Disease: NASH and Related Disorders\u003c\/i\u003e, published by Wiley.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePauline de la M. Hall\u003c\/b\u003e is the editor of \u003ci\u003eFatty Liver Disease: NASH and Related Disorders\u003c\/i\u003e, published by Wiley.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eArthur McCullough, Department Chair of Gastroenterology and Hepatology, Cleveland Clinic, USA\u003c\/b\u003e\u003cbr\u003eArthur McCullough, MD, is Department Chair of Gastroenterology and Hepatology and a Staff Physician in the Department of Pathobiology and Transplantation Center at Cleveland Clinic. He was appointed in 2006. He attended medical school at SUNY Health Science Center at University Hospital of Syracuse, N.Y. He completed his internship and residency at Cleveland Clinic and a fellowship at Mayo Clinic in Rochester, Minn.\u003cbr\u003eHe is one of the most senior hepatologists in the United States and is the current President of the American Association for the Study of Liver Diseases. Other significant achievements are: Best Doctor's in America: \"Midwest Region\" annually from 1996-2008; Chair of the NIH-funded Clinical Research Network on Fatty Liver Disease (federal funding); NIH Grant on Omega 3 Fatty Acids in Diabetes (federal funding); New Novel Agents for Hepatitis C Patients who failed to respond to previous therapy (non-federal funding).\u003c\/p\u003e  Fatty liver disease, especially non-alcoholic steatohepatitis (NASH), is emerging as the most common form of liver disease - affecting at least 5% of the population of western countries with increasing incidence in developing economies in other continents (particularly Asia, South America and South Africa). \u003cbr\u003e \u003cp\u003eNASH is the form of fatty liver disorder which can result in cirrhosis, particularly in those with diabetes or who are overweight, yet it is still not widely recognised despite its already high and increasing prevalence worldwide. This book explains what NASH is, why it happens, who gets it, how it can result in cirrhosis, when to think about it, how to select practical management between those with a minor abnormality from those who may have cirrhosis, and how to prevent and treat this ubiquitous condition.\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e\u003ci\u003eFatty Liver Diseases: NASH and Related Disorders\u003c\/i\u003e\u003c\/b\u003e is an unusual book: it combines a practical approach for students and physicians concerned with the problem with a clear overview on the causative mechanisms. It should appeal to doctors and other health care workers who encounter this problem, as well as to pathologists and investigators interested in the field of liver disease.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989199798501,"sku":"NP9781405112925","price":236.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781405112925.jpg?v=1761783180","url":"https:\/\/k12savings.com\/es\/products\/fatty-liver-disease-isbn-9781405112925","provider":"K12savings","version":"1.0","type":"link"}